Overview

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Status:
Withdrawn
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin tablets when given as monotherapy or add on therapy in participants who are on standard care for management of Type 2 Diabetes Mellitus (T2DM).
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin